# L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release

> **NCT03534661** · PHASE2,PHASE3 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 10 (actual)

## Conditions studied

- Hyperlipidemias

## Interventions

- **DRUG:** Teduglutide + Normal Saline
- **DRUG:** Teduglutide + L-NMMA
- **DRUG:** Placebo + L-NMMA

## Key facts

- **NCT ID:** NCT03534661
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-27
- **Primary completion:** 2019-03-20
- **Final completion:** 2019-03-20
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03534661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03534661, "L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03534661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*